EUCTR2020-000720-19-IT进行中（未招募）1 期
A prospective, randomized, multicenter, open- label, two-arm and parallel-group Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine cream at 1% in patients affected by seborrheic dermatitis. - IDI01/2020
IDI FARMACEUTICI SR0 个研究点目标入组 102 人开始时间: 2021年5月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and female, = 18 years;
- •2.Established diagnosis of seborrheic dermatitis of the face and scalp;
- •3.Able to co-operate and understand written and oral information;
- •4.Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 68
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •1. Concomitant dermatological diseases (eg acne, rosacea, contact dermatitis)
- •2. Recent use of treatments for seborrheic dermatitis (2 weeks for topical treatments; 4 weeks for systemic treatments);
- •3. Hypersensitivity to the active substance or to any of the excipients;
- •4. Established diagnosis of Actinic keratosis;
- •5. Established diagnosis of Parkinson;
- •6. Established diagnosis of HIV infection;
- •7. Use of immunesuppressant medications since last three months;
- •8. Established diagnosis of cardiac diseases;
- •9. Established diagnosis of alcoholic pancreatitis;
- •10. Established diagnosis of other neurological diseases;
- •11. Established diagnosis of Diabetic;
- •12. Pregnancy (positive pregnancy test for women of childbearing potential) and lactation;
- •13. Participation in any other clinical Study within 3 months prior to screening.
研究者
相似试验
招募中
不适用
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter pylori in KoreaCertain infectious and parasitic diseasesKCT0001176Seoul National University Bundang Hospital390
进行中（未招募）
1 期
A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus iron sucrose (VENOFER®) for treatment of iron deficiency anaemia in patients with inflammatory bowel disease Estudio aleatorizado, multicéntrico, prospectivo y abierto para investigar la eficacia y la seguridad de una pauta de dosis de corrección normalizada de carboximaltosa férrica (FERINJECT®) administrada por vía intravenosa en comparación con sacarosa férrica (VENOFER®) para el tratamiento de la anemia ferropénica en pacientes con enfermedad inflamatoria intestinalEUCTR2008-002333-75-ESVifor (International) Inc.420
进行中（未招募）
不适用
A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus iron sucrose (VENOFER®) for treatment of iron deficiency anaemia in patients with inflammatory bowel diseaseIron deficiency anaemia in patients with inflammatory bowel diseaseMedDRA version: 9.1Level: LLTClassification code 10055736Term: Iron deficiency anaemia secondary to blood loss (chronic)EUCTR2008-002333-75-ATVifor (International) Inc.420
进行中（未招募）
不适用
A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus iron sucrose (VENOFER®) for treatment of iron deficiency anaemia in patients with inflammatory bowel diseaseEUCTR2008-002333-75-EEVifor (International) Inc.420
进行中（未招募）
不适用
A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus iron sucrose (VENOFER®) for treatment of iron deficiency anaemia in patients with inflammatory bowel diseaseIron deficiency anaemia in patients with inflammatory bowel diseaseMedDRA version: 9.1Level: LLTClassification code 10055736Term: Iron deficiency anaemia secondary to blood loss (chronic)EUCTR2008-002333-75-DEVifor (International) Inc.420